NT5C2 and myeloid sarcoma: Recent studies on patients affected by haematological malignancies, such as acute myeloid leukaemia (AML) and myelodysplasic syndrome (MS), have demonstrated the involvement of cN-II in the resistance to cytotoxic drugs such as mercaptopurines and suggested the effectiveness of cN-II inhibitors in the treatment of these diseases [4–5].